{"id":19165,"date":"2024-05-04T15:39:27","date_gmt":"2024-05-04T19:39:27","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=19165"},"modified":"2025-01-29T09:23:02","modified_gmt":"2025-01-29T14:23:02","slug":"sentynl","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/ko\/2024\/05\/04\/sentynl\/","title":{"rendered":"PRF\ub294 \ud604\uc7ac \ub85c\ub098\ud30c\ub2d9 \uce58\ub8cc\uc81c(Zokinvy\u00a9)\uc758 \uc0c8\ub85c\uc6b4 \uae00\ub85c\ubc8c \uc18c\uc720\uc8fc\uc778 Sentynl Therapeutics\uc640 \ud611\ub825 \uc911\uc785\ub2c8\ub2e4."},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_image src=&#8221;https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/static1.squarespace.webp&#8221; title_text=&#8221;static1.squarespace&#8221; url=&#8221;https:\/\/www.charitynavigator.org\/ein\/043460220&#8243; align=&#8221;center&#8221; admin_label=&#8221;Sentynl&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; width=&#8221;50%&#8221; max_width=&#8221;50%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.24.3&#8243; text_font_size=&#8221;18px&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>5\uc6d4 3\uc77c \uae08\uc694\uc77c\ubd80\ud130 \uc720\ud6a8\ud569\ub2c8\ub2e4<sup>\ub3c4\ub85c<\/sup>, 2024, <a href=\"https:\/\/url2.mailanyone.net\/scanner?m=1rzcKM-0009Dy-3G&amp;d=4%7Cmail%2F90%2F1713963600%2F1rzcKM-0009Dy-3G%7Cin2m%7C57e1b682%7C18374732%7C14629442%7C662903CE3D97FA99FA9E3F52842D032F&amp;o=%2Fphte%3A%2Fstsonnt%2F.cmyl&amp;s=pj636_P9eRvPUtyP8VtSjuVNKfg\">\uc13c\ud2f0\ub110 \ud14c\ub77c\ud4e8\ud2f1\uc2a4 \uc8fc\uc2dd\ud68c\uc0ac<\/a> (Sentynl)\uc740 Zydus Lifesciences, Ltd\uac00 \uc804\uc561 \uc18c\uc720\ud55c \ubbf8\uad6d \uae30\ubc18 \ubc14\uc774\uc624\uc81c\uc57d \ud68c\uc0ac\ub85c, Eiger BioPharmaceuticals(Eiger)\ub85c\ubd80\ud130 lonafarnib(Zokinvy)\uc5d0 \ub300\ud55c \uae00\ub85c\ubc8c \uad8c\ub9ac\ub97c \uc778\uc218\ud588\uc2b5\ub2c8\ub2e4. Zokinvy\u00ae\ub294 \ud504\ub85c\uac8c\ub9ac\uc544 \uce58\ub8cc\uc81c\ub85c \uc774 \uc57d\uc744 \uc0ac\uc6a9\ud558\ub294 \uc804 \uc138\uacc4 \uac00\uc871\uc5d0\uac8c \uc81c\uacf5\ub429\ub2c8\ub2e4.<\/p>\n<p>\uce98\ub9ac\ud3ec\ub2c8\uc544\uc8fc \uc0cc\ub514\uc5d0\uc774\uace0\uc5d0 \ubcf8\uc0ac\ub97c \ub454 Sentynl\uc740 \ud76c\uadc0 \uc9c8\ud658\uc744 \uc553\uace0 \uc788\ub294 \uc0ac\ub78c\ub4e4\uc758 \uc0b6\uc744 \uc5f0\uc7a5, \uac1c\uc120 \ub610\ub294 \ud5a5\uc0c1\uc2dc\ud0a4\ub294 \uc0c8\ub85c\uc6b4 \uc0dd\ubb3c\uc57d\ud559 \uc758\uc57d\ud488\uc744 \uc81c\uacf5\ud558\ub294 \ub370 \uc911\uc810\uc744 \ub450\uace0 \uc788\uc2b5\ub2c8\ub2e4(https:\/\/sentynl.com\/). PRF\ub294 Eiger\uc640\uc758 \uc131\uacf5\uc801\uc778 \ud30c\ud2b8\ub108\uc2ed\uc5d0 \uac10\uc0ac\ud558\uba70, \uc774\uc81c Sentynl\uacfc \ud798\uc744 \ud569\uce58\uac8c \ub418\uc5b4 \uae30\uc069\ub2c8\ub2e4. PRF\ub294 Eiger\uc640 \ub9c8\ucc2c\uac00\uc9c0\ub85c Sentynl\uacfc \uae34\ubc00\ud788 \ud611\ub825\ud558\uc5ec \uc804 \uc138\uacc4 \ud658\uc790\uc5d0\uac8c Zokinvy\ub97c \uc911\ub2e8 \uc5c6\uc774 \uacf5\uae09\ud558\ub824\ub294 \ud68c\uc0ac\uc758 \ub178\ub825\uc744 \uc9c0\uc6d0\ud560 \uac83\uc785\ub2c8\ub2e4.\u00a0\u00a0<\/p>\n<p>\uc774 \ub274\uc2a4\uc5d0 \ub300\ud55c Sentynl\uc758 \ubcf4\ub3c4 \uc790\ub8cc \ub9c1\ud06c\ub97c \ucc3e\uc744 \uc218 \uc788\uc2b5\ub2c8\ub2e4. <a href=\"https:\/\/www.prnewswire.com\/news-releases\/sentynl-therapeutics-announces-global-acquisition-of-zokinvy-lonafarnib-for-treatment-of-hutchinson-gilford-progeria-syndrome-from-eiger-biopharmaceuticals-302135968.html\">\uc5ec\uae30<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>5\uc6d4 3\uc77c \uae08\uc694\uc77c\ubd80\ud130 Sentynl Therapeutics\uac00 FDA \uc2b9\uc778\uc744 \ubc1b\uc740 \ud504\ub85c\uac8c\ub9ac\uc544 \uce58\ub8cc\uc81c\uc778 Zokinvy\uc758 \uc81c\uc870 \ubc0f \uc720\ud1b5\uc744 \ub2f4\ub2f9\ud558\uac8c \ub429\ub2c8\ub2e4. <\/p>","protected":false},"author":2,"featured_media":18808,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,1],"tags":[],"class_list":["post-19165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sentynl I The Progeria esearch Foundation<\/title>\n<meta name=\"description\" content=\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/ko\/2024\/05\/04\/sentynl\/\" \/>\n<meta property=\"og:locale\" content=\"ko_KR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sentynl I The Progeria esearch Foundation\" \/>\n<meta property=\"og:description\" content=\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/ko\/2024\/05\/04\/sentynl\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-04T19:39:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T14:23:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\ubd84\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)\",\"datePublished\":\"2024-05-04T19:39:27+00:00\",\"dateModified\":\"2025-01-29T14:23:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"},\"wordCount\":266,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"articleSection\":[\"News\",\"Uncategorized\"],\"inLanguage\":\"ko-KR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\",\"name\":\"Sentynl I The Progeria esearch Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"datePublished\":\"2024-05-04T19:39:27+00:00\",\"dateModified\":\"2025-01-29T14:23:02+00:00\",\"description\":\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb\"},\"inLanguage\":\"ko-KR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ko-KR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ko-KR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ko-KR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ko-KR\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/ko\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sentynl I The Progeria esearch Foundation","description":"5\uc6d4 3\uc77c \uae08\uc694\uc77c\ubd80\ud130 Sentynl Therapeutics\uac00 FDA \uc2b9\uc778\uc744 \ubc1b\uc740 \ud504\ub85c\uac8c\ub9ac\uc544 \uce58\ub8cc\uc81c\uc778 Zokinvy\uc758 \uc81c\uc870 \ubc0f \uc720\ud1b5\uc744 \ub2f4\ub2f9\ud558\uac8c \ub429\ub2c8\ub2e4.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/ko\/2024\/05\/04\/sentynl\/","og_locale":"ko_KR","og_type":"article","og_title":"Sentynl I The Progeria esearch Foundation","og_description":"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/ko\/2024\/05\/04\/sentynl\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2024-05-04T19:39:27+00:00","article_modified_time":"2025-01-29T14:23:02+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1\ubd84"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)","datePublished":"2024-05-04T19:39:27+00:00","dateModified":"2025-01-29T14:23:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"},"wordCount":266,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","articleSection":["News","Uncategorized"],"inLanguage":"ko-KR"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/","url":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/","name":"Sentynl I The Progeria esearch Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","datePublished":"2024-05-04T19:39:27+00:00","dateModified":"2025-01-29T14:23:02+00:00","description":"5\uc6d4 3\uc77c \uae08\uc694\uc77c\ubd80\ud130 Sentynl Therapeutics\uac00 FDA \uc2b9\uc778\uc744 \ubc1b\uc740 \ud504\ub85c\uac8c\ub9ac\uc544 \uce58\ub8cc\uc81c\uc778 Zokinvy\uc758 \uc81c\uc870 \ubc0f \uc720\ud1b5\uc744 \ub2f4\ub2f9\ud558\uac8c \ub429\ub2c8\ub2e4.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb"},"inLanguage":"ko-KR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"]}]},{"@type":"ImageObject","inLanguage":"ko-KR","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"\ud504\ub85c\uac8c\ub9ac\uc544 \uc5f0\uad6c \uc7ac\ub2e8","description":"\uc544\uc774\ub4e4\uc744 \uc704\ud574 \u2665 \uce58\ub8cc\ub97c \uc704\ud574","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ko-KR"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"\ud504\ub85c\uac8c\ub9ac\uc544 \uc5f0\uad6c \uc7ac\ub2e8","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"ko-KR","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"\uce74\ub80c \ubca0\ud22c\ub974\ub124\uc774","image":{"@type":"ImageObject","inLanguage":"ko-KR","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/ko\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/posts\/19165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/comments?post=19165"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/posts\/19165\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/media\/18808"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/media?parent=19165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/categories?post=19165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ko\/wp-json\/wp\/v2\/tags?post=19165"}],"curies":[{"name":"\uc6cc\ub4dc\ud504\ub808\uc2a4","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}